ArticleJournal of neurology2010
JCV detection in multiple sclerosis patients treated with natalizumab.
Article in Journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Genetic Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A Genome-Wide and HLA Association Study.Open forum infectious diseases · 2020Article
- Ab locks for improving the selectivity and safety of antibody drugs.Journal of biomedical science · 2020Review
- On the road to new treatments for multiple sclerosis: targeting dendritic cell migration into the central nervous system.Neural regeneration research · 2019Article
- JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy.Journal of neurovirology · 2019Article
- Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.Frontiers in pharmacology · 2016Article
- Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.PloS one · 2016Article
- Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.Journal of neurovirology · 2015Article
- Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.Journal of neurovirology · 2015Article
- JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.Journal of neurovirology · 2015Article
- Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy.Neurology(R) neuroimmunology & neuroinflammation · 2015Article
- JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.Annals of neurology · 2014Article
- Prospective study of BK virus infection in patients with inflammatory bowel disease.TheScientificWorldJournal · 2014Article
- Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2013Observational
- Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.Virology journal · 2013Observational
- JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.Journal of translational medicine · 2012Article
- Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Multiple sclerosis review.P & T : a peer-reviewed journal for formulary management · 2012Article
- Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.CNS drugs · 2012Review
- Managing MS in a changing treatment landscape.Journal of neurology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natalizumab therapy is associated with an increased risk of progressive multifocal leukoencephalopathy (PML). Because the prognosis of established PML is uniformly dismal, identification of highly susceptible patients to the disease may improve outcomes. We wanted to investigate whether serial plasma and cerebrospinal fluid (CSF) screening for polyomavirus would identify patients with laboratory evidence of viral infection prior to the development of clinical PML. Two hundred MS patients had pre-treatment CSF/plasma screening for JC virus (JCV) and BK virus (BKV) DNA, and thereafter every six treatments of natalizumab. In all positive patients treatment is stopped (due to potential risk of PML), they have follow-up clinical examinations and plasma/CSF JCV/BKV tests until all evaluations are normal. No patient developed clinical evidence of PML. Eight of the 200 patients had detectable JCV or BKV DNA. Five patients were positive for BKV DNA in the CSF and three patients were positive for JCV DNA (one in plasma, two in CSF). After cessation of natalizumab treatment, all patients converted to undetectable viral DNA. Screening for JCV in CSF in natalizumab-treated patients could help identify those at heightened risk for developing PML and discontinuing treatment in these patients may abort development of the clinical illness.
Indexed as
Identifiers
20052484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.